Klotho Neurosciences, Inc. (NASDAQ: KLTO) has announced plans to broaden its development programs beyond neurology to include technologies aimed at enhancing muscle strength, bone health, and other indicators of longevity. The company is exploring the acquisition of complementary technologies to support healthy brain function, organ health, and overall longevity. In addition to its core focus on neurodegenerative diseases such as ALS, Alzheimer's, and Parkinson's, Klotho aims to expand its anti-aging platform to slow biological aging and mitigate age-related diseases. The company's efforts will include research into key longevity indicators like alpha-Klotho, beta-Klotho, and FOXO3, with the intention of promoting healthier, longer lives.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.